Clinical application of Hualan gene modified Merlot

People from Hualan Biology (002007 SZ) said in the investigation of securities companies that xiumeile, a monoclonal antibody variety of Hualan gene, a subsidiary of the company, would soon apply for clinical application This means that the company has been promoting the research and development of four monoclonal antibodies, xiumeile, Herceptin, rituximab and Avastin, which are about to enter the clinical stage According to the website of the State Food and Drug Administration (CFDA), Herceptin has been accepted, while rituximab and Avastin have not yet been accepted The original researches of Herceptin (trastuzumab) and rituximab (rituximab injection) are Roche, and their patents are about to expire Many domestic pharmaceutical enterprises, such as Guoyao Tongyi (000028 SZ), Hengrui Pharmaceutical (600276 SH) and CITIC Guojian, have joined the imitation army Hualan bio's monoclonal antibody project is considered to be one of the highlights of the company this year Hualan gene, a joint-stock subsidiary of the company, has been promoting the research and development of four monoclonal antibody varieties, namely xiumeile, Herceptin, meiluohua and Avastin At present, among the four McAb varieties, Herceptin, rituximab and Avastin have applied for clinical application Xie Junmin, chief financial officer and Secretary of the board of directors, said that the clinical application for all four McAbs would be completed within this year, and the approval could be obtained within two years if it is fast